KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Operating Expenses: 2009-2024

Historic Operating Expenses for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $463.8 million.

  • Halozyme Therapeutics' Operating Expenses rose 7.45% to $136.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.5 million, marking a year-over-year increase of 7.46%. This contributed to the annual value of $463.8 million for FY2024, which is 5.66% down from last year.
  • As of FY2024, Halozyme Therapeutics' Operating Expenses stood at $463.8 million, which was down 5.66% from $491.7 million recorded in FY2023.
  • Halozyme Therapeutics' 5-year Operating Expenses high stood at $491.7 million for FY2023, and its period low was $123.3 million during FY2020.
  • In the last 3 years, Halozyme Therapeutics' Operating Expenses had a median value of $463.8 million in 2024 and averaged $449.4 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first tumbled by 53.21% in 2020, then spiked by 134.51% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Operating Expenses (Yearly) stood at $123.3 million in 2020, then surged by 35.73% to $167.4 million in 2021, then soared by 134.51% to $392.6 million in 2022, then rose by 25.24% to $491.7 million in 2023, then fell by 5.66% to $463.8 million in 2024.